NASDAQ · HALO
Halozyme Therapeutics, Inc.
$131.18+$1.15 (+0.88%)
Halozyme Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.03% below the high.
Loading market information…
OTC · SNNAQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sienna Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sienna Biopharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2017 |
|---|
| Mar 15, 2018 |
| -$0.56+29.11% vs estimate |
| $0.00 |
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$131.18+$1.15 (+0.88%)
Halozyme Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.03% below the high.
$207.83+$2.77 (+1.35%)
Jazz Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 21.98% below the high.
$84.95$0.00 (0.0%)
Crinetics Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.07% below the high.
$31.93+$0.20 (+0.63%)
Maze Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.48% below the high.
$17.83-$0.22 (-1.22%)
Janux Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.55% below the high.
$5.59-$0.19 (-3.29%)
PolyPid Ltd.’s quoted price sits in the upper half of its reported 52-week range, 4.28% below the high.
$3.49+$0.28 (+8.72%)
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.14% below the high.
$0.76-$0.15 (-16.31%)
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.08% below the high.
